| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 98.3 | 83.3 |
| Gross profit | 65.1 | 54.0 |
| Profit before tax | -26.6 | -21.4 |
| Net income | -26.5 | -21.4 |
| EPS (diluted, $ a share) | $-0.46 | $-0.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +18.0% |
|---|---|
| Gross margin | 66.3% |
| Operating margin | -27.9% |
10-Q filed with the SEC, NASDAQ: PRCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Procept BioRobotics Corp: key numbers
- Share price
- $23.54Close, Nov 16
- Market cap
- $1.35B
- Shares outstanding
- 57.54MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Procept BioRobotics Corp
All →Procept BioRobotics Chief Strat/Marketing Officer Pooja Sharma Sells $92.9K of Stock
Pooja Sharma, Chief Strat/Marketing Officer, sold 4,710 shares of Procept BioRobotics Corp at $19.71 a share, worth $92.9K in total on Nov 6, 2026. Shares held after the trade: 106,471 (-4.2%).
- Value
- $92.9K
- Shares
- 4,710
- Price
- $19.71
- Role
- Chief Strat/Marketing Officer
- Holding change
- -4.2%
- Trade date
- Nov 6, 2026
Procept BioRobotics Earnings Call: Key Takeaways
Procept BioRobotics delivered a solid Q1 2026 with 20% revenue growth, driven by record system pricing and commercial realignment, while maintaining full-year guidance despite early-quarter procedure disruption and seasonality.
- Call
- Nov 4, 2026, 4:30 PM ET
Procept BioRobotics Financial Results
PROCEPT BioRobotics reported Q3 2026 total revenue of $98.3 million, an increase of 18% year-over-year, driven by strong U.S. procedure growth and the rollout of its HYDROS systems. The company reported a net loss of $26.5 million for the quarter while reaffirming its full-year 2026 revenue guidance of $390 million to $410 million.
- Term
- Q3 2026
“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan. Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027. We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”
Larry Wood, Chief Executive Officer
“This quarter, we continued expanding our installed base and drove strong utilization in HYDROS® accounts. We delivered approximately 18% revenue growth and 22% U.S. procedure growth while accelerating our replacement cycle to transition AquaBeam systems to HYDROS.”
Larry Wood, Chief Executive Officer
Procept BioRobotics Leadership Change
PROCEPT BioRobotics Corporation has expanded its board of directors from nine to ten members and appointed Dr. Michael Mack as a new independent Class II director, effective October 2, 2026. Dr. Mack, a highly published cardiac surgeon and healthcare executive, will serve until the 2029 annual meeting of stockholders. He will receive compensation consistent with the company's existing non-employee director program.
Procept BioRobotics Debt Financing Update with Canadian Imperial Bank of Commerce
PROCEPT BioRobotics Corporation entered into a third amendment to its existing Loan and Security Agreement with CIBC. The amendment extends the maturity date of the term loan by 12 months, from October 1, 2027, to October 1, 2028.
- Counterparty
- Canadian Imperial Bank of Commerce
- Term
- through Oct 2028